Cargando…
Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors
Immune-related adverse events (irAEs) are a range of complications associated with the use of immune-checkpoint inhibitors (ICIs). Two major classes of ICIs widely used are Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Programmed Cell death-1 (PD-1)/Programmed death-ligand 1 (PD-L1) inhibitors. High-...
Autores principales: | Chennamadhavuni, Adithya, Abushahin, Laith, Jin, Ning, Presley, Carolyn J., Manne, Ashish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086893/ https://www.ncbi.nlm.nih.gov/pubmed/35558065 http://dx.doi.org/10.3389/fimmu.2022.779691 |
Ejemplares similares
-
Circulating Tumor DNA in Identifying Resistant Sub-Clones Post EGFR Blockade: Implications for EGFR Rechallenge
por: Chennamadhavuni, Adithya, et al.
Publicado: (2022) -
Biomarkers, Clinical Features, and Rechallenge for Immune Checkpoint Inhibitor Renal Immune-Related Adverse Events
por: Isik, Busra, et al.
Publicado: (2021) -
Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis
por: Gao, Wen, et al.
Publicado: (2022) -
Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer
por: Allouchery, Marion, et al.
Publicado: (2020) -
Immune-Related Adverse Events (irAE) in Cancer Immune Checkpoint Inhibitors (ICI) and Survival Outcomes Correlation: To Rechallenge or Not?
por: Albandar, Heidar J., et al.
Publicado: (2021)